Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBI-5000
- Development stage
- Preclinical
- Lead developer
- Replicate Bioscience
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
01
Overview
RBI-5000 is a self-replicating RNA (srRNA) vaccine candidate being developed by Replicate Bioscience for the prevention or treatment of infectious mononucleosis, which is caused by the Epstein-Barr virus (EBV). The vaccine utilizes Replicate's proprietary srRNA platform to encode multiple EBV-specific antigens. Unlike conventional mRNA vaccines, srRNA is designed to replicate itself within the host cells, leading to sustained protein expression at lower doses. This approach aims to induce a broader, more robust, and more durable immune response against the virus. RBI-5000 is currently in the preclinical stage of development.
Beyond the preview
Go deeper on RBI-5000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBI-5000.